LNS8801 demonstrates exceptional safety in phase 1/2 cancer trials with 100+ patients treated

Linnaeus reported that over 100 cancer patients have been treated with LNS8801 in phase 1/2 studies, showing an exceptional safety and tolerability profile with evidence of biological activity.